XML 85 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Development and Other Agreements - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2018
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
 [1],[2]
Dec. 31, 2019
Dec. 28, 2018
Development Agreements [Line Items]                
Collaborative research and development fee       $ 0.0 $ 87.1 [1],[2] $ 0.0    
Shares Issued In Connection With The Restated Collaboration Agreement       2,945,508        
Gross Carrying Amount $ 195.5 $ 42.8   $ 195.5 $ 42.8      
Verily Life Sciences | Collaborative Arrangement                
Development Agreements [Line Items]                
Amortization period 64 months              
Collaborative Arrangement, Initial Payment | Verily Life Sciences | Collaborative Arrangement                
Development Agreements [Line Items]                
Closing stock price (usd per share)               $ 29.57
Initial payment on collaborative agreement     $ 250.0          
Issuance of common stock in connection with acquisition, shares (in shares)     7,363,772          
Collaborative research and development fee   $ 87.1 $ 217.7          
Collaborative Arrangement, Milestone Payments | Verily Life Sciences | Collaborative Arrangement                
Development Agreements [Line Items]                
Collaborative research and development fee             $ 3.2  
Gross Carrying Amount $ 152.4     $ 152.4        
Potential future common stock issuable (in shares)               5,154,640
[1] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.
[2] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.